Wanbury LimitedWANBURYCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2025 13 quarters of data

₹192.36

MCap ₹673 Cr · P/E 15.8

Wanbury Limited — Stock analysis & AI research Wanbury Limited — Multibagger AI analysis Wanbury Limited — Seasonality — best & worst months Wanbury Limited — Technical setup — score, trend, support & resistance Wanbury Limited — Live exchange announcements

📋 High ROE Stocks 📋 High ROCE Stocks 📋 Promoters Increasing Stake 📈 MACD Bullish Crossover 📈 Multi-Timeframe Bearish Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹163 Cr

Sales · Jun 2025

+24.3% YoY

₹24 Cr

Operating Profit · Jun 2025

+118.7% YoY

14.7%

OPM % · Jun 2025

+75.0% YoY

₹13 Cr

Net Profit · Jun 2025

+1153.1% YoY

₹4.10

EPS · Jun 2025

+1181.2% YoY

📝 Wanbury Limited — results explained

Quarter ended June 2025 (Q1 FY26)

Wanbury Limited reported revenue of ₹163 crore for the quarter ended June 2025 (Q1 FY26), up 24.3% from ₹131 crore in the same quarter last year, and down 5.2% sequentially over the March 2025 quarter.

Net profit rose 1153.1% year-on-year to ₹13 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹4.10.

Operating profit stood at ₹24 crore — an operating margin (OPM) of 14.7%, compared with 8.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY25, Wanbury Limited posted revenue of ₹598 crore, a growth of 6.3% over FY24, with a net profit of ₹31 crore (down 41.6% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹629 crore with a net profit of ₹42 crore.

Valuation snapshot

At the current price of ₹192.36, WANBURY has a market capitalisation of ₹673 crore and a trailing P/E of about 15.8.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 43.01%, foreign institutional investors (FIIs) 0.59%, public shareholders 56.39% of Wanbury Limited.

Promoter holding slipped from 43.08% to 43.01% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹673 Cr

Current Price ?

₹192.4

P/E ?

15.84below ind

Industry P/E ?

37.20

P/B ?

11.40

P/S ?

1.07

P/FCF ?

-29.24

Enterprise Value ?

₹852 Cr

EV/EBITDA ?

9.72

PEG ?

0.20

Earnings Yield ?

8.7%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹629 Cr

OPM ?

13.9%

Profit after tax (TTM) ?

₹42 Cr

EPS (TTM) ?

₹12.15

ROCE ?

37.0%

ROE ?

72.0%

ROA ?

10.3%

Growth

Sales — latest qtr ?

₹163 Cr

PAT — latest qtr ?

₹13 Cr

YoY qtr sales growth ?

24.3%

YoY qtr profit growth ?

1,153.1%

Sales growth (3y) ?

Sales growth (5y) ?

10%

Profit growth (3y) ?

80%

Profit growth (5y) ?

31%

Financial Health

Debt ?

₹179 Cr

Debt to Equity ?

3.03

Interest Coverage ?

1.7

Current Ratio ?

N/A

Ownership

Promoter holding ?

43.01%

Change in promoter holding ?

3.38%

Pledged percentage ?

N/A

Market

Return 3 months ?

-42.1%

Return 6 months ?

-25.9%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	YoY %	QoQ %
Sales	117	124	126	133	133	144	145	139	131	161	133	172	163	+24.3%	-5.2%
Operating Profit	-3	6	6	14	14	17	21	18	11	20	14	30	24	+118.7%	-19.0%
Other Income	2	1	0	-3	-2	1	1	1	1	2	1	2	0	-100.0%	-100.0%
Interest	3	4	7	8	8	8	8	7	8	10	10	9	8	+5.4%	-11.5%
Depreciation	3	3	3	3	3	3	3	3	3	3	3	3	4	+21.6%	+18.6%
Profit Before Tax	-7	-1	-3	1	1	7	10	34	1	8	1	19	14	+1249.5%	-26.5%
Net Profit	-7	-1	-3	1	1	7	10	34	1	8	1	20	13	+1153.1%	-35.8%
EPS	-2.21	-0.27	-1.00	0.31	0.31	2.25	3.14	10.28	0.32	2.45	0.38	6.18	4.10	+1181.2%	-33.7%
OPM %	-2.6%	4.8%	5.1%	10.5%	10.7%	12.0%	14.5%	13.0%	8.4%	12.4%	10.4%	17.2%	14.7%	+75.0%	-14.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY24	FY25	TTM	YoY %
Sales	₹562 Cr	₹598 Cr	₹629 Cr	+6.3%
Operating Profit	₹71 Cr	₹75 Cr	₹88 Cr	+5.3%
OPM %	12.59%	12.47%	13.91%	-1.0%
NPM %	9.30%	5.11%	6.75%	-45.1%
Other Income	₹0 Cr	₹6 Cr	₹5 Cr	+1703.9%
Depreciation	₹13 Cr	₹13 Cr	₹14 Cr	+0.5%
Interest	₹31 Cr	₹37 Cr	₹37 Cr	+19.1%
EBIT	₹58 Cr	₹62 Cr	₹74 Cr	+6.3%
PBT	₹52 Cr	₹29 Cr	₹42 Cr	-43.8%
Tax	₹-0 Cr	₹-1 Cr	₹-1 Cr	-6695.2%
Net Profit	₹52 Cr	₹31 Cr	₹42 Cr	-41.6%
EPS	₹15.98	₹9.33	₹13.11	-41.6%
Material Cost	₹287 Cr	₹213 Cr	₹145 Cr	-25.9%
Employee Cost	₹87 Cr	₹78 Cr	₹53 Cr	-10.0%
Extraordinary Items	₹25 Cr	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	% Chg
Equity Capital	33	33	33	33	+0.0%
Reserves	-56	-66	-5	26	+620.0%
Borrowings	100	95	116	179	+54.3%
Other Liabilities	276	241	199	176	-11.6%
Total Liabilities	353	304	343	414	+20.7%
Fixed Assets	167	167	167	201	+20.4%
CWIP	2	2	3	5	+66.7%
Investments	0	0	0	0	—
Other Assets	183	135	174	208	+19.5%
Total Assets	353	304	343	414	+20.7%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	% Chg
Cash from Operating Activity	41	20	4	26	+550.0%
Cash from Investing Activity	1	-9	-17	-51	-200.0%
Cash from Financing Activity	-29	-32	15	26	+73.3%
Net Cash Flow	13	-21	2	1	-50.0%
Free Cash Flow	42	7	-10	-23	-130.0%
CFO/OP	113%	76%	6%	33%	+450.0%

➗ Ratios (latest 4 periods)

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	% Chg
Debtor Days	45	52	59	70	+18.6%
Inventory Days	60	26	43	47	+9.3%
Days Payable	218	179	196	172	-12.2%
Cash Conversion Cycle	-113	-101	-94	-55	+41.5%
Working Capital Days	-153	-152	-40	4	+110.0%
ROCE %	46%	21%	61%	37%	-39.3%

👥 Shareholding (latest 4 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	% Chg
Promoters	39.63%	43.09%	43.08%	43.01%	-0.2%
FIIs	1.59%	0.82%	0.72%	0.59%	-18.1%
Public	58.79%	56.08%	56.21%	56.39%	+0.3%
No. of Shareholders	17,894	17,717	17,261	16,732	-3.1%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	WANBURY Wanbury	₹239.00	836	14.9	653	56	15.2%	8.6%	8.8%	117.8%	1.5%	-76.0%

❓ Frequently asked questions

What was Wanbury Limited's revenue in Q1 FY26?

What was Wanbury Limited's net profit in Q1 FY26?